Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (May 2023)
23 slides from Sonoma Pharmaceuticals's investor presentation, May 10, 2023
Slide 1: Sonoma Pharmaceuticals, Inc. May 2023
Sonoma Pharmaceuticals, Inc. May 2023
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness
Slide 3: About Sonoma
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid ( HOCl ) products for a wide range of applications, including dermatology, wound care, eye care, nasal care, oral care, podiatry, animal health and non - toxic disinfectants. Sonoma’s produ
Slide 4: Investor Highlights
Investor Highlights Diverse global healthcare leader • Focused on billion - dollar markets in Rx and OTC dermatology, wound care, eye, oral and nasal care, podiatry, animal health and n on - toxic disinfectants, treating common injuries, infections and irritations • Over 20 years of experience with
Slide 5: Expand distribution
Expand distribution • Expand Rx and OTC reach in U.S. in the dermatology, wound care, eye, oral and nasal care, podiatry, animal care and non - toxic di sinfectants markets via direct - to - consumer sales and distribution partnerships • Increase sales of dermatology products through the direct disp
Slide 6: Robust International Distribution Network
Robust International Distribution Network Established and growing distribution network with OVER 40 GLOBAL PARTNERS generating strong revenues internationally and in the U.S. • Expand presence in new markets by replicating what works in existing markets • Continue to add new distribution partners an
Slide 7: Continuously expanding our distributor network
Continuously expanding our distributor network • Entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. , one of the largest pharmaceutical companies in South Korea, in January 2023 for the marketing and distribution of Primocyn TM Skin Solution products • Sonoma’s Microcyn ® R
Slide 8: Expanding commercialization opportunities by investing in R&D
Expanding commercialization opportunities by investing in R &D • In March 2023, Sonoma announced new EPA claims for its Nanocyn ® Hospital - Grade Disinfectant f or effective use against MRSA , Salmonella , Norovirus , Poliovirus , and as a fungicide . Nanocyn was previously approved for use against
Slide 9: New Market Opportunities
• The global natural skin care products market size was valued at $6.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030. 1 • The global medical spa market size was valued at $16.4 billion in 2022 and is expected to expand at a compound annua
Slide 10: Sonoma's Microcyn Technology
Sonoma’s Microcyn ® Technology Stable triple - action topical technology • A powerful anti - microbial – reduces microbial load, including destruction of biofilms • Anti - inflammatory agent – reduces itch and pain • Anti - pruritic activity • Tissue healing (increased blood/oxygen flow to wound) Un
Slide 11: What is Hypochlorous Acid?
What is Hypochlorous Acid? During the activation of neutrophils, respiratory bursts generate hydrogen peroxide (H 2 O 2 ) and the activated granule enzyme myeloperoxidase converts H 2 O 2 to hypochlorous acid (HOCl) • Produced by neutrophils in the body as part of its defense mechanism • Highly acti
Slide 12: Research articles and clinical studies on Microcyn technology
Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn ® technology • Dermodacyn ® Disinfecting solution study on viability of SARS - CoV - 2, see https://www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn ® study on cellul
Slide 13: Diverse Product Portfolio - United States
Diverse Product Portfolio United States Podiacyn Everyday Foot Care Microcyn Rx Skin & Wound Care Regenacyn Scar Gel Epicyn Antimicrobial Facial Cleanser Nanocyn Hospital Grade Disinfectant Levicyn Antimicrobial Dermal Spray Celacyn Scar Management Gel Rejuvacyn Skin Repair Reliefacyn Itch, Burn, Ra
Slide 14: U.S. Animal Health Care
U.S. Animal Health Care MicrocynAH ® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail cha
Slide 15: U.S. office dispense products
U.S. office dispense products exclusively for skin care professionals • Generates highest margins for Sonoma • Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin
Slide 16: Direct-to-consumer products
Direct - to - consumer products available through Shopify , Amazon and Amazon EU U.S. Products EU Products
Slide 17: EU Products
Epicyn ® Dermatology Gramaderm ® Dermatology Pediacyn ® Dermatology Mucoclyns ® Decontamination solution Microdacyn60 ® Oral Care Blocked nose or sinuses Sinudox ® Nasal care Blepharitis treatment Ocudox ® Eye lid solution Exposure to germs and pathogens Mouth and throat infections Keloid or hypertr
Slide 18: Middle East products
& Middle East Microdacyn Microsafe Disinfectant & Sanitizer
Slide 19: Latin America and Australia/New Zealand products
Gramacyn Kit for Acne Skin Latin America Epicyn Treat Scars Right from the Start Australia and New Zealand
Slide 20: Asia products
Asia Singapore, Malaysia, Thailand, Indonesia Wound Care South Korea BioDerm Biodacyn60 Wound Care Hong K ong Microdacyn60 Oral Care China Microcyn The Philippines M icrodacyn MicrocynAH
Slide 21: Cutting Edge Manufacturing
• 57,153 square foot state - of - the - art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Shipping to over 55 countries • Highly trained staff of 153 employees CUTTING EDGE MANUFACTURING Flexible operat
Slide 22: Manufacturing facility in Guadalajara, Mexico
Located in Guadalajara, Mexio Laboratory Packaging Area Labeling Boxing Ready for shipment Warehouse Air Systems Product Water Treatment System Materials Testing Laboratory Manufacturing Facility
Slide 23: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court , Suite 150 Boulder , CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court , Suite 150 Boulder , CO 8
Sonoma Pharmaceuticals — Investor Presentation (May 2023) on 6ix